MicroRNA-205 Inhibits Src-Mediated Oncogenic Pathways in Renal Cancer

  • Shahana Majid
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Sharanjot Saini
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Altaf A. Dar
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Hiroshi Hirata
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Varahram Shahryari
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Yuichiro Tanaka
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Soichiro Yamamura
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Koji Ueno
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Mohd Saif Zaman
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Kamaldeep Singh
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Inik Chang
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Guoren Deng
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California
  • Rajvir Dahiya
    Authors' Affiliations: 1Department of Urology, VA Medical Center and University of California San Francisco; and 2California Pacific Medical Center Research Institute, San Francisco, California

書誌事項

公開日
2011-03-31
DOI
  • 10.1158/0008-5472.can-10-3666
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>The Src family of protein kinases (SFK) plays key roles in regulating fundamental cellular processes, including cell growth, differentiation, cell shape, migration, and survival, and specialized cell signals in various malignancies. The pleiotropic functions of SFKs in cancer make them promising targets for intervention. Here, we sought to investigate the role of microRNA-205 (miR-205) in inhibition of Src-mediated oncogenic pathways in renal cancer. We report that expression of miR-205 was significantly suppressed in renal cancer cell lines and tumors when compared with normal tissues and a nonmalignant cell line and is correlated inversely with the expression of SFKs. miR-205 significantly suppressed the luciferase activity of reporter plasmids containing the 3′-UTR (untranslated region) sequences complementary to either Src, Lyn, or Yes, which was abolished by mutations in these 3′-UTR regions. Overexpression of miR-205 in A498 cells reduced Src, Lyn, and Yes expression, both at mRNA and protein levels. Proliferation of renal cancer cells was suppressed by miR-205, mediated by the phospho-Src–regulated ERK1/2 pathway. Cell motility factor FAK (focal adhesion kinase) and STAT3 activation were also inhibited by miR-205. Transient and stable overexpression of miR-205 in A498 cells resulted in induction of G0/G1 cell-cycle arrest and apoptosis, as indicated by decreased levels of cyclin D1 and c-Myc, suppressed cell proliferation, colony formation, migration, and invasion in renal cancer cells. miR-205 also inhibited tumor cell growth in vivo. This is the first study showing that miR-205 inhibits proto-oncogenic SFKs, indicating a therapeutic potential of miR-205 in the treatment of renal cancer. Cancer Res; 71(7); 2611–21. ©2011 AACR.</jats:p>

収録刊行物

  • Cancer Research

    Cancer Research 71 (7), 2611-2621, 2011-03-31

    American Association for Cancer Research (AACR)

被引用文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ